Wealth Enhancement Advisory Services LLC Invests $301,000 in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Wealth Enhancement Advisory Services LLC purchased a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 13,564 shares of the company's stock, valued at approximately $301,000.

Other hedge funds also recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at $61,000. KLP Kapitalforvaltning AS acquired a new position in Kiniksa Pharmaceuticals International in the 4th quarter worth $158,000. Bellevue Group AG bought a new position in Kiniksa Pharmaceuticals International during the 4th quarter worth about $160,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Kiniksa Pharmaceuticals International by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after purchasing an additional 4,575 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on KNSA shares. Jefferies Financial Group increased their price objective on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday, July 6th. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price for the company. Finally, Wedbush reissued an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, April 16th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of "Buy" and an average target price of $39.33.

Kiniksa Pharmaceuticals International Trading Down 3.1%

Shares of KNSA traded down $0.89 during midday trading on Friday, reaching $28.06. The stock had a trading volume of 271,046 shares, compared to its average volume of 556,024. The firm has a 50 day simple moving average of $27.71 and a 200-day simple moving average of $23.10. The firm has a market cap of $2.05 billion, a PE ratio of -112.24 and a beta of 0.05. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $30.69.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The firm had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. During the same quarter in the previous year, the business earned ($0.25) earnings per share. The business's revenue was up 72.5% compared to the same quarter last year. As a group, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Michael R. Megna sold 15,211 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $28.75, for a total value of $437,316.25. Following the transaction, the chief accounting officer owned 32,546 shares in the company, valued at approximately $935,697.50. This represents a 31.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eben Tessari sold 17,300 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $28.28, for a total transaction of $489,244.00. Following the completion of the transaction, the chief operating officer directly owned 61,563 shares in the company, valued at approximately $1,741,001.64. This represents a 21.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 440,863 shares of company stock worth $12,101,029 in the last quarter. Company insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.